Amgen Reports Strong Q1 2025 Financial Results

Amgen Inc ( (AMGN) ) has released its Q1 earnings. Here is a breakdown of the information Amgen Inc presented to its investors.

Amgen Inc., a leading biotechnology company, focuses on discovering, developing, manufacturing, and delivering innovative medicines for serious illnesses, with a strong presence in the biotechnology sector. In its first quarter of 2025, Amgen reported a 9% increase in total revenues, reaching $8.1 billion, driven by strong global demand and successful product launches. The company’s product sales grew by 11%, with notable performances from Repatha, BLINCYTO, and TEZSPIRE, among others. Amgen’s GAAP earnings per share rose to $3.20, compared to a loss in the previous year, due to gains from equity investments. Non-GAAP EPS increased by 24% to $4.90, reflecting higher revenues despite increased operating expenses. The company also generated $1.0 billion in free cash flow, doubling from the previous year. Looking ahead, Amgen remains optimistic about its growth prospects, supported by ongoing product launches and a robust pipeline, anticipating total revenues between $34.3 billion and $35.7 billion for the full year 2025.